Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 17, 2026.

Activation of PAD4 in NET formation

Amanda S. Rohrbach, Daniel J. Slade, Paul R. Thompson and 1 more

Frontiers in Immunology · 2012

doi:10.3389/fimmu.2012.00360

Abstract

Peptidylarginine deiminases, or PADs, convert arginine residues to the non-ribosomally encoded amino acid citrulline in a variety of protein substrates. PAD4 is expressed in granulocytes and is essential for the formation of neutrophil extracellular traps (NETs) via PAD4-mediated histone citrullination. Citrullination of histones is thought to promote NET formation by inducing chromatin decondensation and facilitating the expulsion of chromosomal DNA that is coated with antimicrobial molecules. Numerous stimuli have been reported to lead to PAD4 activation and NET formation. However, how this signaling process proceeds and how PAD4 becomes activated in cells is largely unknown. Herein, we describe the various stimuli and signaling pathways that have been implicated in PAD4 activation and NET formation, including the role of reactive oxygen species generation. To provide a foundation for the above discussion, we first describe PAD4 structure and function, and how these studies led to the development of PAD-specific inhibitors. A comprehensive survey of the receptors and signaling pathways that regulate PAD4 activation will be important for our understanding of innate immunity, and the identification of signaling intermediates in PAD4 activation may also lead to the generation of pharmaceuticals to target NET-related pathogenesis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

THE PEPTIDYL ARGININE DEIMINASE FAMILY

The mammalian genome encodes 20 natural amino acids; however, this diversity is greatly increased by posttranslational modification of the original set to yield more than one hundred unique amino acids. Citrullination, or deimination, is the posttranslational modification of an arginine to a citrulline residue. Hydrolysis of the guanidino group of the arginine yields a ureido group and the loss of an ammonia (Figure 1). Citrullination is catalyzed by the peptidyl arginine deiminase family of enzymes, or PADs. This process results in the loss of positive charge and an approximately 1 Da increase in mass. While this modification seems quite modest, the loss of positive charge, and hydrogen bond acceptors, can have dramatic effects on cell signaling because these types of interactions are critical for stabilizing protein–protein, protein–DNA, and protein–RNA interactions. Additionally, this PTM may disrupt intra-molecular interactions, which could trigger major conformational changes in a protein, potentially altering intermolecular interactions and decreasing protein stability.

Five PAD enzymes are expressed in humans and mice, and the major difference between these isozymes appears to be tissue localization. PADs 1, 3, and 6 are expressed in the skin and uterus, hair follicles, and egg, ovary and embryo, respectively. PAD4 expression has been reported in granulocytes, as well as some cancerous cell lines and tumors, and most recently in mammalian oocytes and the preimplantation embryo. PAD2 has a much broader tissue expression profile and can be found in the CNS, skeletal muscle, and cells of the immune system. PADs 1, 2, and 4 are the only PADs expressed in the hematopoietic lineage, and, thus, are especially of immunological interest.

PADI genes, encoding the PAD enzymes, are located in a single gene cluster on chromosome 1p36.1 in humans and chromosome 4pE1 in mice. The regions encoding the PADI locus in humans and mice span 334.7 and 230.4 kb, respectively. All PAD enzymes are highly conserved, sharing at least 50% sequence homology among isozymes and 70% or greater homology of each vertebrate ortholog. Eighteen per cent sequence identity is shared among all PADs. Catalysis by all of these enzymes is calcium dependent, and, at least in vitro, requires calcium concentrations that are higher than that available in homeostatic cytoplasm, indicating calcium flux or a calcium-producing event is necessary to induce activity. Alternatively, a PTM or interacting protein may decrease the calcium concentration required for activation to physiologic levels.

PAD4

Of all of the PADs, PAD4 is of specific interest because of its importance in innate immunity and its putative role in a variety of pathogenic states, including autoimmune diseases, such as rheumatoid arthritis (RA), multiple sclerosis (MS), ulcerative colitis (UC), and systemic lupus erythematosus (SLE), and other inflammatory conditions, such as sepsis and thrombosis. Many autoantibodies in RA are directed against citrullinated proteins. In fact, the presence of anti-citrullinated protein antibodies (ACPA) is a better predictor of RA than rheumatoid factor, and, in 2011, ACPA were included in the new classification criteria for RA. A genome-wide association study identified a PAD4 haplotype that is associated with RA in a Japanese population, albeit with a low odds ratio (OR = 1.14; ). The mutations in the PAD4 gene appear to confer prolonged stability to the transcript, leading to a model where increased expression of PAD4 in these populations would favor the generation of citrullinated self-epitopes to prime the autoimmune response. Though this association has been confirmed in other Asian populations, it has not been replicated in studies using patients from all Western European populations, indicating that the RA-associated PAD4 haplotype found in Asian RA patients can not explain the presence of ACPA’s in all ethnicities. Interestingly, the PAD4 RA-associated disease haplotype has also been found in some Japanese patients with UC. MS patients have increased levels of the citrullinated form of myelin basic protein, and both PAD2 and PAD4 are overexpressed in the brains of MS patients. Finally, as will be discussed later in this review, in response to microbes, neutrophils can extrude their nuclear contents to form antimicrobial neutrophil extracellular traps (NETs; ). Since PAD4 is essential for the formation of NETs, PAD4 has also been implicated in NET-related pathologies, such as SLE and thrombosis, where NETs presumably promote deleterious inflammatory responses. Thus, PAD4 may be a relevant target for several disease indications.

PAD4 is a 74 kDa protein that exists as a head-to-tail dimer. Each monomer consists of two N-terminal immunoglobulin (Ig) domains, formed by Ig subdomain 1, which contains nine β-sheets, and Ig subdomain 2, which contains 10 β-sheets and four short α-helices. The C-terminal catalytic domain adopts the α/β propeller fold that is characteristic of the deiminase superfamily. The C-terminal catalytic domain is the most highly conserved area of the molecule, suggesting that the active sites are likely quite similar among PADs. While a high degree of conservation exists among PADs, PAD4 is the only family member to contain a classic nuclear localization sequence (56-PPAKKKST-63), found in Ig1 near the N-terminus, and, thus, is trafficked to the nucleus. However, it is worth noting that recent data indicates that other PADs, most notably PAD2, are localized to the nucleus.

PAD4 binds five calcium molecules, designated Ca1–Ca5, in a cooperative manner. Ca1 and Ca2 bind in the C-terminal catalytic domain, and their binding induces major conformational changes that move several active site residues into positions that are competent for catalysis. This calcium-induced formation of the active site is unique to the PADs, and represents a novel mechanism of enzyme activation. Calcium binding also induces large structural changes in the N-terminus of the protein. For example, binding of Ca3, Ca4, and Ca5, along with two water molecules, induces the formation of the a1 α-helix, which is disordered in the apoenzyme. These conformational changes may provide, or remove, docking sites for other proteins, which may serve to further regulate PAD activity.

BIOCHEMICAL ACTIVATION OF PAD4

While it is unknown whether all PAD enzymes are capable of multimerizing, the dimer has been suggested to be required for PAD4 activity. However, the effects on enzyme activity and the calcium dependence of the enzyme are relatively minor (approximately twofold), and we routinely see robust enzyme activity at concentrations of protein that are an order of magnitude below the Kd of the dimer. Nevertheless, dimer formation may represent a possible regulatory mechanism. Dimerization is mediated by both hydrophobic interactions and salt bridges between adjacent monomers.

The PADs display limited substrate specificity and citrullinate many proteins in vitro, preferring to modify arginine residues present in unstructured regions; the rate of substrate turnover is inversely proportional to the structural order of the substrate. Structurally, PAD4 interacts with the backbone atoms surrounding the site deimination, i.e., R-2, R-1, R0, and (R + 1), with few, if any, contacts with the side chains. The only requirement appears to be a small side chain at the R-2 position so as to avoid steric contacts with the active site. Upon binding to PAD4 the backbone of the substrate adopts a β-turn-like conformation within the substrate binding cleft, thereby explaining why the enzymes show such a high level of substrate promiscuity. In contrast to the situation in vitro, the PADs are believed to show greater substrate specificity in vivo. Presumably, interacting proteins modulate the substrate specificity of the enzyme or spatially target the enzyme to specific regions of the cell. For example, PAD4 is present in the nucleus and may be targeted to chromatin where it citrullinates a number of nuclear proteins, including the histones and protein arginine methyltransferase 1 (PRMT1;; ). Although PAD4 was reported to convert monomethylated arginine residues to citrulline, this modification occurs at rates that are 102- to 103-fold slower than an unmodified arginine, suggesting that the, so-called “demethylimination” reaction is not physiologically relevant and that citrullination simply antagonizes arginine methylation as originally suggested by.

In addition to the aforementioned protein substrates, PAD4, as well as the other PADs, autocitrullinate at several sites on the enzyme. Although autocitrullination has been reported to directly modulate PAD4 activity, in our hands, this self-modification has no direct effect on enzyme activity, but it does appear to modulate protein–protein interactions. For example, demonstrated that citrullination of PAD4 reduces its ability to interact with PRMT1 and histone deacetylase (HDAC) 1, perhaps modulating its ability to alter gene transcription.

PAD MECHANISM AND INHIBITION

Given the substrate promiscuity of the PADs, it is unsurprising that the PADs also citrullinate a number of small molecule arginine mimics, including benzoyl arginine ethyl ester (BAEE) and benzoyl arginine amide (BAA). In fact, these compounds have served as important mechanistic probes of PAD4 catalysis and provided the molecular scaffold for the construction of the first highly potent PAD4 inhibitors. Below we highlight key mechanistic insights that guided the design of these inhibitors.

Briefly, there are four key catalytic residues, Asp350, His471, Asp473, and Cys645. Asp473 binds to both ω-nitrogens and Asp350 coordinates to one ω-nitrogen and the δ-nitrogen (Figure 2A). Cys645 and His471 lie on opposite sides of the guanidinium group and are appropriately positioned to promote catalysis via nucleophilic attack on the guanidinium carbon (Cys645) and protonation of the developing tetrahedral intermediate (His471; Figure 2B). Collapse of this intermediate leads to the loss of ammonia and the formation of the stable S-alkyl thiouronium intermediate that is subsequently hydrolyzed via a second tetrahedral intermediate to form citrulline; His471 likely activates the water molecule for nucleophilic attack (Figure 2B). Mechanistic studies, including mutagenesis, pH rate profile, solvent isotope effects, and solvent viscosity effects, as well as crystal structures of PAD4 bound to several substrates (i.e., BAA; ), and histone H3 and histone H4 tail analogs;, ), and inhibitors (i.e., F-amidine, Cl-amidine, o-F-amidine, o-Cl-amidine, and TDFA;;; ), provide strong support for the above mechanism and helped drive our thoughts about inhibitor design. For example, the presence of a reactive active site Cys prompted us to consider the synthesis of irreversible inhibitors. Additionally, the fact that mono-methylated arginine residues were exceptionally poor PAD substrates, as well as the steric restraints of the active site, told us that the reactive moiety would have to be relatively isosteric with respect to the substrate guanidinium. Furthermore, mutagenesis studies on the two active site aspartyl groups in PAD4, Asp350 and Asp473, showed that these residues are critical for catalysis, indicating that proper positioning, hydrogen bonding, and electrostatic interactions between these residues and the substrate guanidinium are critical determinants for efficient substrate turnover, and would have to be maintained for efficient enzyme inactivation. As such, we initially focused our efforts on synthesizing F-amidine and Cl-amidine (Figure 2C), two haloacetamidine-containing compounds that we hypothesized, and later confirmed, would inactivate the PADs by alkylating Cys645. These initial inhibitors, F-amidine and Cl-amidine, as well as our second generation compounds o-F-amidine, o-Cl-amidine, and TDFA, which show enhanced potency and selectivity, are bioavailable and have been used to show that the PADs play important roles in controlling gene transcription, fertility, differentiation, and NET formation. Additionally, Cl-amidine, or a Cl-amidine analog, decrease disease severity in animal models of RA, UC, nerve damage, and cancer. Specifically, we were the first to show that the PAD inhibitor, Cl-amidine dose dependently decreased inflammation by up to 55% in the mouse collagen-induced arthritis (CIA) model of RA. Concomitant with the decreased severity there were significant decreases in the levels of citrullinated proteins, complement deposition, and epitope spreading. Similar dose-dependent effects were observed in the dextran sodium sulfate (DSS) model of UC where dosing of up to 75 mg/kg after the onset of disease led to significant reductions in weight loss, inflammation score, and colon lengthening. The effects of Cl-amidine on nerve damage was examined in a chick embryo model of spinal cord injury where treatment with Cl-amidine reduced the abundance of deiminated histone 3, consistent with inhibition of PAD activity, and significantly reduced apoptosis and tissue loss following injury at embryonic day 15. Finally, showed that a Cl-amidine analog, YW3-56, decreased tumor growth in a mouse sarcoma S-180 cell-derived solid tumor model and that additive effects on growth inhibition were observed when this compound was combined with the histone deacetylase inhibitor SAHA. We have observed similar effects with Cl-amidine in xenografts model of ductal carcinoma in situ.

THE FUNCTION OF PAD4 IN NEUTROPHILS

Neutrophils are terminally differentiated granulocytes, which differentiate from hematopoietic stem cells in the bone marrow, and make up to 75% of white blood cells in the circulation. Mature neutrophils are released into circulation, where they have a very short life span of several hours to one day before undergoing apoptosis. Neutrophils are an important component of the innate immune system and form the first line of defense against invading pathogens, such as bacteria and fungi. Neutrophils contain an arsenal of antimicrobial proteins and peptides in primary (or azurophilic), secondary (or specific), and tertiary granules. Primary granules are mostly composed of proteases, such as myeloperoxidase and neutrophil elastase (NE), and antimicrobial peptides, such as defensins. Secondary and tertiary granules contain lactoferrin and gelatinase, respectively. Secretory granules also harbor stores of membrane proteins, such as the NADPH oxidase machinery (Nox; ), which can be trafficked to the surface of the cell quickly when necessary. In response to chemoattractants, neutrophils are guided to areas of infection, where they respond with several effector mechanisms to invading pathogens, including phagocytosis, release of bactericidal products, and ROS production. Neutropenia, or the state of having too few neutrophils, leads to extreme immunosuppression and susceptibility to bacterial infections, which can be fatal.

In 2004, recognized the formation of NET structures, which were extruded by neutrophils in response to bacteria. NETs are composed of nuclear DNA that are decorated with a variety of nuclear and granular proteins, actively thrown out into the extracellular space, and result in death of the NET-producing cell. Cell death by this mechanism is unique from apoptosis and necrosis and has been termed “NETosis”. NETs ensnare extracellular bacteria, which are killed by the inherent antimicrobial properties of NET-associated proteins, such as histones, NE, and lactoferrin. These structures represent a novel method for pathogen killing, independent of both degranulation and phagocytosis, and have been shown to effectively kill a variety of pathogens, including bacteria, fungi, and protozoa. NETs have also been reported to occur in response to viral infection; however, they not appear to show any observable anti-viral capabilities. NETs may represent a killing mechanism for pathogens too large for the neutrophil to phagocytose, such as fungal hyphae or helminthes. Interestingly, bacteria have adapted defense mechanisms to NET formation. For example, the Group A Streptococcus express a DNase enzyme that can degrade NETs, and Pseudomonas aeruginosa expresses surface molecules that can prevent neutrophil activation and NET formation.

Histone citrullination is thought to promote NET formation by inducing chromatin decondensation and facilitating the expulsion of chromosomal DNA coated with antimicrobial molecules. In fact, chemical inhibition of PAD4 activity significantly reduces histone decondensation and NET formation in response to either the calcium ionophore ionomycin or the bacterium Shigella flexneri. Our group and the Wang group have independently created PAD4-deficient mice. Neutrophils isolated from PAD4-deficient mice are unable to citrullinate histones, decondense chromatin, and generate NETs. Because of their inability to form NETs, PAD4 KO mice were shown to be more susceptible to bacterial infection, and, thus, PAD4 is an important mediator of innate immunity.

Neutrophil elastase, a neutrophil serine protease, resides in the azurophilic granules and is a component of NETs. The cleavage of microbial virulence factors by NE is essential for the clearance of specific Gram-negative bacteria. NE also cleaves histones to drive chromatin decondensation during NET formation. Indeed, NE is essential for the process of NETosis, and it is interesting to speculate that histone citrullination, by PAD4, promotes a relaxing of the chromatin structure, allowing NE to gain access. Thus, the activity of NE and PAD4 may converge upon the chromatin decondensation process and NET formation. Neutrophils isolated from PAD4-deficient mice will be useful to delineate the hierarchy between PAD4 and other molecules, like NE, that are required for NETosis.

STIMULATION OF PAD4 ACTIVITY

A number of stimuli, including live and heat-killed bacteria, fungi, protozoa, and chemokines have been reported to induce NET formation. Because NET formation is PAD4-dependent, these same stimuli likely also induce PAD4 activation. However, the activity of PAD4 in relation to each stimuli must be assessed by looking for citrullination of histones, which is both a hallmark of PAD activity and a component of NETs. Only a handful these, including live bacteria, the Gram-negative bacterial cell wall component lipopolysaccharide (LPS), the Gram-positive bacterial cell wall component lipoteichoic acid (LTA), the fungal cell wall component zymosan, the proinflammatory cytokine TNFα, and H2O2 have been shown to induce PAD4 activity and histone citrullination. As discussed earlier, PAD4 is calcium-dependent, and it is thought that PAD4 requires calcium levels higher than are found in the homeostatic cell to be active. Not surprisingly, the calcium ionophore ionomycin activates PAD4 to induce histone citrullination and elicit NET formation. Table 1 catalogs the variety of stimuli reported to stimulate NET formation.

Although little is known about the downstream signaling pathways required for PAD4 activation in neutrophils, cytoskeletal activity may be involved in PAD4 activation. Pretreatment of cells with nocodazole or cytochalasin D, which inhibit microtubule polymerization, prior to LPS stimulation leads to a reduction of histone citrullination and NET formation. Additionally, blockade of integrin signaling through Mac-1 and cytohesin-1 impeded PAD4 activity and NET formation. How cytoskeletal signaling impacts PAD4 is unknown; however, it has been proposed that the same receptors establish whether a cell will undergo phagocytosis or NET formation. Indeed, studies have indicated that neutrophils initiate NET formation when phagocytosis of a large particle fails. Perhaps cytoskeletal activity and PAD4-mediated citrullination are linked because the initiation of NET formation represents a back-up killing mechanism following unsuccessful phagocytosis.

PAD4 ACTIVITY AND ROS

The generation of reactive oxygen species (ROS) is initiated by a wide variety of neutrophil stimuli, including phagocytosis of pathogens and signaling by LPS and TNF, which are also NET-inducing stimuli. Indeed, ROS generation is required for NET formation, and, thus, it is likely that ROS generation is required for PAD4 activation as well. In neutrophils, superoxide is generated by the NADPH complex (Nox) and by the electron transport chain in mitochondria. is then converted to H2O2 spontaneously or by the enzyme superoxide dismutase (SOD; ). H2O2 acts directly on target cells and is converted to additional effectors by enzymes such as myeloperoxidase (MPO). Interestingly, the addition of H2O2 to primary murine or human neutrophils induces PAD4-dependent histone citrullination. ROS molecules are highly cytotoxic and act as antimicrobial agents, but they can also play a dual role as reversible signal transduction mediators to regulate redox-sensitive target proteins.

The link between ROS and NET formation was first recognized by the fact that patients with chronic granulomas disease (CGD), who are missing the Nox2 protein essential for NADPH assembly and, thus, cannot form ROS. Neutrophils isolated from CGD patients do not make NETs in response to S. aureus or phorbol myristate acetate (PMA; ). This phenotype is rescued by addition of H2O2 or exogenous glucose oxidase, which generates H2O2, indicating that the ROS production facilitated by Nox2 is necessary for NETs. Catalase removes intracellular H2O2 by reduction to water and oxygen, and catalase inhibition increases intracellular H2O2 leading to increased NET production in healthy neutrophils. Subsequent studies have demonstrated that ROS generation is upstream of chromatin decondensation, suggesting that NADPH oxidase activation may also be a prerequisite for PAD4 activation. Indeed, LPS-induced citrullination of histone H4 is decreased when cells are pre-incubated with the NADPH oxidase inhibitor apocynin. Although, to our knowledge, the activity of PAD4 in CGD neutrophils has not yet been directly explored, since chromatin decondensation is not observed in CGD neutrophils, we would predict PAD4-mediated histone citrullination is also impaired. Since H2O2 treatment can activate PAD4-mediated histone deimination in primary murine and human neutrophils, and since NADPH activation seems to be upstream of NET formation, we speculate that PAD4 activation may be downstream of NADPH (Figure 3).

The contribution of specific ROS molecules to NET formation has also been examined. NADPH oxidase or mitochondrial ROS selective inhibitors established a requirement for NADPH oxidase generated, but excluded a need for mitochondrial ROS in PMA-induced NET generation. MPO catalyzes the oxidation of Cl- ions to generate hypochlorous acid (HOCl) and other reactive products using H2O2 as a cosubstrate. In the absence of MPO activity, NET generation is absent, but this phenotype can be rescued by addition of HOCl. In fact, the HOCl product of MPO has also been found to be both necessary and sufficient for NET formation, and in CGD neutrophils, the addition of HOCl is also sufficient to initiate NET formation. Taurine is a cellular antioxidant capable of reducing HOCl and H2O2 to promote cell survival. Accordingly, preincubation of neutrophils with taurine prior to PMA or HOCl stimulation reduces NET formation. Additionally, while SOD inhibition does not impede NET formation, addition of exogenous SOD does seem to increase NET production, perhaps owing to the increase in available H2O2. These studies indicate a model in which NADPH oxidase activity generates, which then dismutates to H2O2 either spontaneously or with the help of SOD, and is then used by MPO to generate HOCl, which is necessary and sufficient to induce NET formation. It will be interesting to determine whether HOCl can also directly regulate PAD4 activation.

PAD4 AND AUTOPHAGY

Like ROS, autophagy has been shown to be required for chromatin decondensation during NET generation; however, these two processes seem to be independent of each other. Blockade of PI3K with wortmannin inhibits autophagy, and pretreatment of PMA stimulated neutrophils with wortmannin prevented chromatin decondensation. However, no direct role between autophagy, PI3K and citrullination has been shown. Recently, newly developed PAD4 inhibitors were found to reduce autophagy processes in an osteosarcoma cell line, further providing evidence of a link between PAD4 activity and autophagy.

CONCLUSION

Neutrophil extracellular traps have been reported in several pathological scenarios, including SLE, sepsis, thrombosis, and infectious disease, and may induce or exacerbate inflammation through prolonged inflammatory response, tissue damage, and presentation of neo-antigens. Indeed, our group recently described the PAD4-dependent formation of NETs in a murine model of the effector phase of RA; however, PAD4 was dispensable for disease in this model. Pathology caused or exacerbated by NETs is an expanding field of research. Because PAD4 is required for NET formation, inhibition of PAD4 activity may improve clinical outcomes in patients experiencing these inflammatory diseases. In fact, PAD inhibitors have demonstrated efficacy in a variety of immune pathologies. Of course, because PAD4 is required for microbial-induced NET formation, the side effects of PAD4-targeted therapeutics may also include increased susceptibility to infectious diseases.

PAD4 is an important component in the innate immune system, however its activity has been linked to a wide variety of disease states, including cancer, autoimmunity, and other inflammatory conditions. Despite its significance, little is understood about how the PAD4 enzyme becomes active in order to impart its helpful and harmful effects. At the protein level, calcium binding, dimerization, and autocitrullination may help regulate its activity. ROS may also play a role in regulating PAD4 activation (see model in Figure 3), and recently associations between PAD4 activity and autophagy have been proposed. Despite these efforts, much is left to understand about PAD4 enzyme regulation. Anti-PAD4 therapies have been proposed for inflammatory conditions and cancer, thus a more comprehensive understanding of the pathways that activate PAD4 in neutrophils will be important.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 113

  1. 1.

    Abi Abdallah D. S. Lin C. Ball C. J. King M. R. Duhamel G. E. Denkers E. Y. (2012 ). Toxoplasma gondii triggers release of human and mouse neutrophil extracellular traps. Infect. Immun. 80 768–777

    Not in our library10.1128/iai.05730-11

  2. 2.

    Amulic B. Cazalet C. Hayes G. L. Metzler K. D. Zychlinsky A. (2012 ). Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 30 459–489

    Not in our library10.1146/annurev-immunol-020711-074942

  3. 3.

    Andrade F. Darrah E. Gucek M. Cole R. N. Rosen A. Zhu X. (2010 ). Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activation. Arthritis Rheum. 62 1630–1640

    Not in our library10.1002/art.27439

  4. 4.

    Arita K. Hashimoto H. Shimizu T. Nakashima K. Yamada M. Sato M. (2004 ). Structural basis for Ca2+-induced activation of human PAD4. Nat. Struct. Mol. Biol. 11 777–783

    Not in our library10.1038/nsmb799

  5. 5.

    Arita K. Shimizu T. Hashimoto H. Hidaka Y. Yamada M. Sato M. (2006 ). Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc. Natl. Acad. Sci. U.S.A. 103 5291–5296

    Not in our library10.1073/pnas.0509639103

  6. 6.

    Arnhold J. Flemmig J. (2010 ). Human myeloperoxidase in innate and acquired immunity. Arch. Biochem. Biophys. 500 92–106

    Not in our library10.1016/j.abb.2010.04.008

  7. 7.

    Beiter K. Wartha F. Albiger B. Normark S. Zychlinsky A. Henriques-Normark B. (2006 ). An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr. Biol. 16 401–407

    Not in our library10.1016/j.cub.2006.01.056

  8. 8.

    Borregaard N. (2010 ). Neutrophils, from marrow to microbes. Immunity 33 657–670

    Not in our library10.1016/j.immuni.2010.11.011

  9. 9.

    Brahmajosyula M. Miyake M. (2011 ). Localization and expression of peptidylarginine deiminase 4 (PAD4) in mammalian oocytes and preimplantation embryos. Zygote 1–11.

    Not in our library

  10. 10.

    Brinkmann V. Zychlinsky A. (2007 ). Beneficial suicide: why neutrophils die to make NETs. Nat. Rev. Microbiol. 5 577–582

    Not in our library10.1038/nrmicro1710

  11. 11.

    Brinkmann V. Reichard U. Goosmann C. Fauler B. Uhlemann Y. Weiss D. S. et al. (2004 ). Neutrophil extracellular traps kill bacteria. Science 303 1532–1535

    Not in our library10.1126/science.1092385

  12. 12.
  13. 13.

    Buchanan J. T. Simpson A. J. Aziz R. K. Liu G. Y. Kristian S. A. Kotb M. et al. (2006 ). DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol. 16 396–400

    Not in our library10.1016/j.cub.2005.12.039

  14. 14.

    Casutt-Meyer S. Renzi F. Schmaler M. Jann N. J. Amstutz M. Cornelis G. R. (2010 ). Oligomeric coiled-coil adhesin YadA is a double-edged sword. PLoS ONE 5 e15159

    Not in our library10.1371/journal.pone.0015159

  15. 15.

    Causey C. P. Jones J. E. Slack J. L. Kamei D. Jones L. E. Subramanian V. et al. (2011 ). The development of N-alpha-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-L-ornithine amide (o-F-amidine) and N-alpha-(2-carboxyl)benzoyl-N(5)-(2-chloro-1- iminoethyl)-L-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors. J. Med. Chem. 54 6919–6935

    Not in our library10.1021/jm2008985

  16. 16.
  17. 17.

    Chen C. C. Isomoto H. Narumi Y. Sato K. Oishi Y. Kobayashi T. et al. (2008 ). Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population. Clin. Immunol. 126 165–171

    Not in our library10.1016/j.clim.2007.09.001

  18. 18.

    Chow O. A. von Kockritz-Blickwede M. Bright A. T. Hensler M. E. Zinkernagel A. S. Cogen A. L. et al. (2010 ). Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 8 445–454

    Not in our library10.1016/j.chom.2010.10.005

  19. 19.

    Chumanevich A. A. Causey C. P. Knuckley B. A. Jones J. E. Poudyal D. Chumanevich A. P. et al. (2011 ). Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am. J. Physiol. Gastrointest. Liver Physiol. 300 G929–G938

    Not in our library10.1152/ajpgi.00435.2010

  20. 20.

    Clark S. R. Ma A. C. Tavener S. A. McDonald B. Goodarzi Z. Kelly M. M. et al. (2007 ). Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med. 13 463–469

    Not in our library10.1038/nm1565

  21. 21.
  22. 22.

    Crotty Alexander L. E. Maisey H. C. Timmer A. M. Rooijakkers S. H. Gallo R. L. von Kockritz-Blickwede M. et al. (2010 ). M1T1 group A streptococcal pili promote epithelial colonization but diminish systemic virulence through neutrophil extracellular entrapment. J. Mol. Med. (Berl.) 88 371–381

    Not in our library10.1007/s00109-009-0566-9

  23. 23.

    Cuthbert G. L. Daujat S. Snowden A. W. Erdjument-Bromage H. Hagiwara T. Yamada M. et al. (2004 ). Histone deimination antagonizes arginine methylation. Cell 118 545–553

    Not in our library10.1016/j.cell.2004.08.020

  24. 24.

    Ermert D. Urban C. F. Laube B. Goosmann C. Zychlinsky A. Brinkmann V. (2009a ). Mouse neutrophil extracellular traps in microbial infections. J. Innate Immun. 1 181–193

    Not in our library10.1159/000205281

  25. 25.

    Ermert D. Zychlinsky A. Urban C. (2009b ). Fungal and bacterial killing by neutrophils. Methods Mol. Biol. 470 293–312

    Not in our library10.1007/978-1-59745-204-5_21

  26. 26.

    Fuchs T. A. Abed U. Goosmann C. Hurwitz R. Schulze I. Wahn V. et al. (2007 ). Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176 231–241

    Not in our library10.1083/jcb.200606027

  27. 27.

    Fuchs T. A. Brill A. Duerschmied D. Schatzberg D. Monestier M. Myers D. D. Jr. (2010 ). Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. U.S.A. 107 15880–15885

    Not in our library10.1073/pnas.1005743107

  28. 28.

    Gabriel C. McMaster W. R. Girard D. Descoteaux A. (2010 ). Leishmania donovani promastigotes evade the antimicrobial activity of neutrophil extracellular traps. J. Immunol. 185 4319–4327

    Not in our library10.4049/jimmunol.1000893

  29. 29.

    Garcia-Romo G. S. Caielli S. Vega B. Connolly J. Allantaz F. Xu Z. (2011 ). Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3 73ra20

    Not in our library10.1126/scitranslmed.3001201

  30. 30.

    Grinberg N. Elazar S. Rosenshine I. Shpigel N. Y. (2008 ). Beta-hydroxybutyrate abrogates formation of bovine neutrophil extracellular traps and bactericidal activity against mammary pathogenic Escherichia coli. Infect. Immun. 76 2802–2807

    Not in our library10.1128/iai.00051-08

  31. 31.

    Guimaraes-Costa A. B. Nascimento M. T. Froment G. S. Soares R. P. Morgado F. N. Conceicao-Silva F. et al. (2009 ). Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc. Natl. Acad. Sci. U.S.A. 106 6748–6753

    Not in our library10.1073/pnas.0900226106

  32. 32.
  33. 33.

    Gupta A. K. Hasler P. Holzgreve W. Gebhardt S. Hahn S. (2005 ). Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum. Immunol. 66 1146–1154

    Not in our library10.1016/j.humimm.2005.11.003

  34. 34.

    Gupta A. K. Joshi M. B. Philippova M. Erne P. Hasler P. Hahn S. et al. (2010 ). Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett. 584 3193–3197

    Not in our library10.1016/j.febslet.2010.06.006

  35. 35.

    Hakkim A. Furnrohr B. G. Amann K. Laube B. Abed U. A. Brinkmann V. et al. (2010 ). Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U.S.A. 107 9813–9818

    Not in our library10.1073/pnas.0909927107

  36. 36.
  37. 37.

    Hidaka Y. Hagiwara T. Yamada M. (2005 ). Methylation of the guanidino group of arginine residues prevents citrullination by peptidylarginine deiminase IV. FEBS Lett. 579 4088–4092

    Not in our library10.1016/j.febslet.2005.06.035

  38. 38.

    Janeway C. (2005 ). Immunobiology: The Immune System in Health and Disease, 6th Edn. New York: Garland Science

    Not in our library

  39. 39.

    Jones J. E. Causey C. P. Knuckley B. Slack-Noyes J. L. Thompson P. R. (2009 ). Protein arginine deiminase 4 (PAD4): current understanding and future therapeutic potential. Curr. Opin. Drug Discov. Dev. 12 616–627

    Not in our library

  40. 40.

    Jones J. E. Slack J. L. Fang P. Zhang X. Subramanian V. Causey C. P. et al. (2012 ). Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem. Biol. 7 160–165

    Not in our library10.1021/cb200258q

  41. 41.

    Juneau R. A. Pang B. Weimer K. E. Armbruster C. E. Swords W. E. (2011 ). Nontypeable Haemophilus influenzae initiates formation of neutrophil extracellular traps. Infect. Immun. 79 431–438

    Not in our library10.1128/iai.00660-10

  42. 42.

    Kan R. Jin M. Subramanian V. Causey C. P. Thompson P. R. Coonrod S. A. (2012 ). Potential role for PADI-mediated histone citrullination in preimplantation development. BMC Dev. Biol. 12 19

    Not in our library10.1186/1471-213x-12-19

  43. 43.

    Kearney P. L. Bhatia M. Jones N. G. Yuan L. Glascock M. C. Catchings K. L. et al. (2005 ). Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry 44 10570–10582

    Not in our library10.1021/bi050292m

  44. 44.

    Kessenbrock K. Krumbholz M. Schonermarck U. Back W. Gross W. L. Werb Z. et al. (2009 ). Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15 623–625

    Not in our library10.1038/nm.1959

  45. 45.

    Khatua B. Bhattacharya K. Mandal C. (2012 ). Sialoglycoproteins adsorbed by Pseudomonas aeruginosa facilitate their survival by impeding neutrophil extracellular trap through siglec-9. J. Leukoc. Biol. 91 641–655

    Not in our library10.1189/jlb.0511260

  46. 46.
  47. 47.

    Klareskog L. Ronnelid J. Lundberg K. Padyukov L. Alfredsson L. (2008 ). Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 26 651–675

    Not in our library10.1146/annurev.immunol.26.021607.090244

  48. 48.

    Knuckley B. Bhatia M. Thompson P. R. (2007 ). Protein arginine deiminase 4: evidence for a reverse protonation mechanism. Biochemistry 46 6578–6587

    Not in our library10.1021/bi700095s

  49. 49.

    Knuckley B. Causey C. P. Jones J. E. Bhatia M. Dreyton C. J. Osborne T. C. et al. (2010 ). Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry 49 1–28

    Not in our library10.1021/bi100363t

  50. 50.

    Kohchi C. Inagawa H. Nishizawa T. Soma G. (2009 ). ROS and innate immunity. Anticancer Res. 29 817–821

    Not in our library

  51. 51.

    Lange S. Gogel S. Leung K. Y. Vernay B. Nicholas A. P. Causey C. P. Thompson P. R. et al. (2011 ). Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability. Dev. Biol. 355 205–214

    Not in our library10.1016/j.ydbio.2011.04.015

  52. 52.

    Lauth X. von Kockritz-Blickwede M. McNamara C. W. Myskowski S. Zinkernagel A. S. Beall B. et al. (2009 ). M1 protein allows Group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition. J. Innate Immun. 1 202–214

    Not in our library10.1159/000203645

  53. 53.

    Li P. Li M. Lindberg M. R. Kennett M. J. Xiong N. Wang Y. (2010 ). PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207 1853–1862

    Not in our library10.1084/jem.20100239

  54. 54.

    Li P. Yao H. Zhang Z. Li M. Luo Y. Thompson P. R. et al. (2008 ). Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol. Cell. Biol. 28 4745–4758

    Not in our library10.1128/mcb.01747-07

  55. 55.

    Lin A. M. Rubin C. J. Khandpur R. Wang J. Y. Riblett M. Yalavarthi S. et al. (2011 ). Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 187 490–500

    Not in our library10.4049/jimmunol.1100123

  56. 56.
  57. 57.

    Logters T. Margraf S. Altrichter J. Cinatl J. Mitzner S. Windolf J. et al. (2009 ). The clinical value of neutrophil extracellular traps. Med. Microbiol. Immunol. 198 211–219

    Not in our library10.1007/s00430-009-0121-x

  58. 58.

    Luo Y. Arita K. Bhatia M. Knuckley B. Lee Y. H. Stallcup M. R. et al. (2006a ) Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry 45 11727–11736

    Not in our library10.1021/bi061180d

  59. 59.

    Luo Y. Knuckley B. Bhatia M. Pellechia P. J. Thompson P. R. (2006b ) Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe. J. Am. Chem. Soc. 128 14468–14469

    Not in our library10.1021/ja0656907

  60. 60.

    Mantovani A. Cassatella M. A. Costantini C. Jaillon S. (2011 ). Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11 519–531

    Not in our library10.1038/nri3024

  61. 61.

    Marcos V. Zhou Z. Yildirim A. O. Bohla A. Hector A. Vitkov L. et al. (2011 ). Retraction: CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat. Med. 17 899

    Not in our library10.1038/nm0711-899a

  62. 62.

    McCormick A. Heesemann L. Wagener J. Marcos V. Hartl D. Loeffler J. et al. (2010 ). NETs formed by human neutrophils inhibit growth of the pathogenic mold Aspergillus fumigatus. Microbes Infect. 12 928–936

    Not in our library10.1016/j.micinf.2010.06.009

  63. 63.

    McElwee J. L. Mohanan S. Griffith O. L. Breuer H. C. Anguish L. J. Cherrington B. D. et al. (2012 ). Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer 12, 500,

    Not in our library

  64. 64.

    Mechin M. C. Coudane F. Adoue V. Arnaud J. Duplan H. Charveron M. et al. (2010 ). Deimination is regulated at multiple levels including auto-deimination of peptidylarginine deiminases. Cell. Mol. Life Sci. 67 1491–1503

    Not in our library10.1007/s00018-010-0262-5

  65. 65.

    Menegazzi R. Decleva E. Dri P. (2012 ). Killing by neutrophil extracellular traps: fact or folklore? Blood 119 1214–1216

    Not in our library10.1182/blood-2011-07-364604

  66. 66.

    Metzler K. D. Fuchs T. A. Nauseef W. M. Reumaux D. Roesler J. Schulze I. et al. (2011 ). Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. Blood 117 953–959

    Not in our library10.1182/blood-2010-06-290171

  67. 67.

    Mori Y. Yamaguchi M. Terao Y. Hamada S. Ooshima T. Kawabata S. (2012 ). alpha-Enolase of Streptococcus pneumoniae induces formation of neutrophil extracellular traps. J. Biol. Chem. 287 10472–10481

    Not in our library10.1074/jbc.m111.280321

  68. 68.

    Moscarello M. A. Mastronardi F. G. Wood D. D. (2007 ). The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem. Res. 32 251–256

    Not in our library10.1007/s11064-006-9144-5

  69. 69.

    Munafo D. B. Johnson J. L. Brzezinska A. A. Ellis B. A. Wood M. R. Catz S. D. (2009 ). DNase I inhibits a late phase of reactive oxygen species production in neutrophils. J. Innate Immun. 1 527–542

    Not in our library10.1159/000235860

  70. 70.

    Nakashima K. Hagiwara T. Yamada M. (2002 ). Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J. Biol. Chem. 277 49562–49568

    Not in our library10.1074/jbc.m208795200

  71. 71.

    Neeli I. Dwivedi N. Khan S. Radic M. (2009 ). Regulation of extracellular chromatin release from neutrophils. J. Innate Immun. 1 194–201

    Not in our library10.1159/000206974

  72. 72.

    Neeli I. Khan S. N. Radic M. (2008 ). Histone deimination as a response to inflammatory stimuli in neutrophils. J. Immunol. 180 1895–1902

    Not in our library10.4049/jimmunol.180.3.1895

  73. 73.

    Nishinaka Y. Arai T. Adachi S. Takaori-Kondo A. Yamashita K. (2011 ). Singlet oxygen is essential for neutrophil extracellular trap formation. Biochem. Biophys. Res. Commun. 413 75–79

    Not in our library10.1016/j.bbrc.2011.08.052

  74. 74.

    Oehmcke S. Morgelin M. Herwald H. (2009 ). Activation of the human contact system on neutrophil extracellular traps. J. Innate Immun. 1 225–230

    Not in our library10.1159/000203700

  75. 75.

    Palmer L. J. Cooper P. R. Ling M. R. Wright H. J. Huissoon A. Chapple I. L. (2012 ). Hypochlorous acid regulates neutrophil extracellular trap release in humans. Clin. Exp. Immunol. 167 261–268

    Not in our library10.1111/j.1365-2249.2011.04518.x

  76. 76.

    Papayannopoulos V. Zychlinsky A. (2009 ). NETs: a new strategy for using old weapons. Trends Immunol. 30 513–521

    Not in our library10.1016/j.it.2009.07.011

  77. 77.

    Papayannopoulos V. Metzler K. D. Hakkim A. Zychlinsky A. (2010 ). Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J. Cell Biol. 191 677–691

    Not in our library10.1083/jcb.201006052

  78. 78.

    Parker H. Albrett A. M. Kettle A. J. Winterbourn C. C. (2012 ). Myeloperoxidase associated with neutrophil extracellular traps is active and mediates bacterial killing in the presence of hydrogen peroxide. J. Leukoc. Biol. 91 369–376

    Not in our library10.1189/jlb.0711387

  79. 79.

    Parseghian M. H. Luhrs K. A. (2006 ). Beyond the walls of the nucleus: the role of histones in cellular signaling and innate immunity. Biochem. Cell Biol. 84 589–604

    Not in our library10.1139/o06-082

  80. 80.

    Patel S. Kumar S. Jyoti A. Srinag B. S. Keshari R. S. Saluja R. et al. (2010 ). Nitric oxide donors release extracellular traps from human neutrophils by augmenting free radical generation. Nitric Oxide 22 226–234

    Not in our library10.1016/j.niox.2010.01.001

  81. 81.

    Pham C. T. (2006 ). Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. Immunol. 6 541–550

    Not in our library10.1038/nri1841

  82. 82.

    Pilsczek F. H. Salina D. Poon K. K. Fahey C. Yipp B. G. Sibley C. D. et al. (2010 ). A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus. J. Immunol. 185 7413–7425

    Not in our library10.4049/jimmunol.1000675

  83. 83.

    Raijmakers R. Zendman A. J. Egberts W. V. Vossenaar E. R. Raats J. Soede-Huijbregts C. et al. (2007 ). Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. J. Mol. Biol. 367 1118–1129

    Not in our library10.1016/j.jmb.2007.01.054

  84. 84.

    Ramos-Kichik V. Mondragon-Flores R. Mondragon-Castelan M. Gonzalez-Pozos S. Muniz-Hernandez S. Rojas-Espinosa O. et al. (2009 ). Neutrophil extracellular traps are induced by Mycobacterium tuberculosis. Tuberculosis (Edinb.) 89 29–37

    Not in our library10.1016/j.tube.2008.09.009

  85. 85.

    Remijsen Q. Kuijpers T. W. Wirawan E. Lippens S. Vandenabeele P Vanden Berghe T. (2011a ). Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. Cell Death Differ. 18 581–588

    Not in our library10.1038/cdd.2011.1

  86. 86.

    Remijsen Q. Vanden Berghe T. Wirawan E. Asselbergh B. Parthoens E. De Rycke R. et al. (2011b ). Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. Cell Res. 21 290–304

    Not in our library10.1038/cr.2010.150

  87. 87.

    Rohrbach A. S. Hemmers S. Arandjelovic S. Corr M. Mowen K. A. (2012 ). PAD4 is not essential for disease in the K/BxN murine autoantibody-mediated model of arthritis. Arthritis Res. Ther. 14 R104

    Not in our library10.1186/ar3829

  88. 88.

    Shirai H. Blundell T. L. Mizuguchi K. (2001 ). A novel superfamily of enzymes that catalyze the modification of guanidino groups. Trends Biochem. Sci. 26 465–468

    Not in our library10.1016/s0968-0004(01)01906-5

  89. 89.

    Slack J. L. Causey C. P. Luo Y. Thompson P. R. (2011a ). Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4. ACS Chem. Biol. 6 466–476

    Not in our library10.1021/cb1003515

  90. 90.

    Slack J. L. Jones L. E. Jr. Bhatia M. M. Thompson P. R. (2011b ). Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity. Biochemistry 50 3997–4010

    Not in our library10.1021/bi200309e

  91. 91.

    Slack J. L. Causey C. P. Thompson P. R. (2011c ). Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell. Mol. Life Sci. 68 709–720

    Not in our library10.1007/s00018-010-0480-x

  92. 92.

    Springer D. J. Ren P. Raina R. Dong Y. Behr M. J. McEwen B. F. et al. (2010 ). Extracellular fibrils of pathogenic yeast Cryptococcus gattii are important for ecological niche, murine virulence and human neutrophil interactions. PLoS ONE 5 e10978

    Not in our library10.1371/journal.pone.0010978

  93. 93.

    Suzuki A. Yamada R. Chang X. Tokuhiro S. Sawada T. Suzuki M. et al. (2003 ). Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34 395–402

    Not in our library10.1038/ng1206

  94. 94.

    Svobodova E. Staib P. Losse J. Hennicke F. Barz D. Jozsi M. (2012 ). Differential interaction of the two related fungal species Candida albicans and Candida dubliniensis with human neutrophils. J. Immunol. 189 2502–2511

    Not in our library10.4049/jimmunol.1200185

  95. 95.

    Thompson P. R. Fast W. (2006 ). Histone citrullination by protein arginine deiminase: is arginine methylation a green light or a roadblock? ACS Chem. Biol. 1 433–441

    Not in our library10.1021/cb6002306

  96. 96.
  97. 97.

    Urban C. F. Reichard U. Brinkmann V. Zychlinsky A. (2006 ). Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell. Microbiol. 8 668–676

    Not in our library10.1111/j.1462-5822.2005.00659.x

  98. 98.

    Uy R. Wold F. (1977 ). Posttranslational covalent modification of proteins. Science 198 890–896

    Not in our library10.1126/science.337487

  99. 99.

    Villanueva E. Yalavarthi S. Berthier C. C. Hodgin J. B. Khandpur R. Lin A. M. et al. (2011 ). Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187 538–552

    Not in our library10.4049/jimmunol.1100450

  100. 100.

    Vossenaar E. R. Radstake T. R. van der Heijden A. van Mansum M. A. Dieteren C. de Rooij D. J. et al. (2004 ). Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 63 373–381

    Not in our library10.1136/ard.2003.012211

  101. 101.

    Vossenaar E. R. Zendman A. J. van Venrooij W. J. Pruijn G. J. (2003 ). PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25 1106–1118

    Not in our library10.1002/bies.10357

  102. 102.

    Wang Y. Li M. Stadler S. Correll S. Li P. Wang D. et al. (2009 ). Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184 205–213

    Not in our library10.1083/jcb.200806072

  103. 103.

    Wang Y. Li P. Wang S. Hu J. Chen X. A. Wu J. et al. (2012 ). Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J. Biol. Chem. 287 25941–25953

    Not in our library10.1074/jbc.m112.375725

  104. 104.

    Wang Y. Wysocka J. Sayegh J. Lee Y. H. Perlin J. R. Leonelli L. et al. (2004 ). Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306 279–283

    Not in our library10.1126/science.1101400

  105. 105.

    Willemze A. Trouw L. A. Toes R. E. Huizinga T. W. (2012 ). The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 8 144–152

    Not in our library10.1038/nrrheum.2011.204

  106. 106.

    Willis V. C. Gizinski A. M. Banda N. K. Causey C. P. Knuckley B. Cordova K. N. et al. (2011 ). N-{alpha}-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J. Immunol. 186 4396–4404

    Not in our library10.4049/jimmunol.1001620

  107. 107.

    Wood D. D. Ackerley C. A. Brand B. Zhang L. Raijmakers R. Mastronardi F. G. et al. (2008 ). Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities. Lab. Invest. 88 354–364

    Not in our library10.1038/labinvest.3700748

  108. 108.

    Wood D. D. Bilbao J. M. O’Connors P. Moscarello M. A. (1996 ). Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann. Neurol. 40 18–24

    Not in our library10.1002/ana.410400106

  109. 109.

    Yan J. Meng X. Wancket L. M. Lintner K. Nelin L. D. Chen B. et al. (2012 ). Glutathione reductase facilitates host defense by sustaining phagocytic oxidative burst and promoting the development of neutrophil extracellular traps. J. Immunol. 188 2316–2327

    Not in our library10.4049/jimmunol.1102683

  110. 110.

    Yao H. Li P. Venters B. J. Zheng S. Thompson P. R. Pugh B. F. et al. (2008 ). Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J. Biol. Chem. 283 20060–20068

    Not in our library10.1074/jbc.m802940200

  111. 111.

    Yost C. C. Cody M. J. Harris E. S. Thornton N. L. McInturff A. M. Martinez M. L. et al. (2009 ). Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates. Blood 113 6419–6427

    Not in our library10.1182/blood-2008-07-171629

  112. 112.

    Zhang X. Bolt M. Guertin M. J. Chen W. Zhang S. Cherrington B. D. et al. (2012 ). Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor alpha target gene activation. Proc. Natl. Acad. Sci. U.S.A. 109 13331–13336

    Not in our library10.1073/pnas.1203280109

  113. 113.

    Zhang X. Gamble M. J. Stadler S. Cherrington B. D. Causey C. P. Thompson P. R. et al. (2011 ). Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. PLoS Genet. 7 e1002112

    Not in our library10.1371/journal.pgen.1002112

Cited by papers we hold 13

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.